1. Шерлок Ш., Дули Дж. Заболевания печени и желчных путей. М.: ГЕО-
ТАР, 2002; 859.
2. Aijaz Ahmed MD, Emmet B, Keeffe MD. Hepatitis C virus and liver transplantation.
Clin Liver Dis 2001; 5 (4).
3. V.Mazzaferro и et al. Liver transplantation for treatment of small hepatocellular
Carcinomas in patients with cirrhosis. N Eng J Med 1996; 334 (11):
693–9
4. Alberti A, Belli L, Arnold A et al. Combined therapy with interferon and lowdose
ribavirin in post-transplantation recurrent hepatitis С: а pragmatic
study. Liver Transpl 2001; 7: 870–6.
5. Berenguer M, Crippin J, Gish R et al. A model to predict severe HCV-related
disease following liver transplantation. Hepatology 2003; 38: 34–41.
6. Albeniz Arbizu E, Barcena Marugan R, Oton Nieto E et al. Prophylaxis of
recurrent hepatitis В virus by vaccination after liver transplant: preliminary
results. Transplant Proc 2003; 35: 1848–9.
7. Alonso I, Herreros de Tejada A, Moreno IM et al. Effectiveness of low-dose
intramuscular anti-VHB immune globulin in the prophylaxis of viral В
hepatitis reinfection after liver transplantation: preliminary report. Transplant
Proc 2003; 35: 1850–1.
8. Berenguer M, Lopez-Labrador FX, Wright TL. Hepatitis C and transplantation.
J Hepatol 2001; 35: 666–78.
9. Berenguer M, Prieto M, Rayon JM et al. Natural history of clinically compensated
hepatitis С virus-related graft cirrhosis after liver transplantation.
Hepatol 2000; 32: 852–8.
10. Berenguer M, Rayon JM, Prieto M et al. Are posttransplantation protocol
liver biopsies useful in the long term? Liver Transpl 2001; 7: 790–6.
11. Beckebaum S, Malago M, Dirsch O et al. Efficacy of combined lamivudine
and adefovir dipivoxil treatment for severe HBV graft reinfection after living
donor liver transplantation. Clin Transplant 2003; 17: 554–9.
12. Bizollon T, Palazzo U, Ducerf C et al. Pilot study of the combination of
interferon alfa and ribavirin as therapy of recurrent hepatitis С after liver
transplantation. J Hepatol 1997; 26: 500–4.
13. Chalasani N, Manzarbeitia C, Ferenci P et al. Peginterferon alfa-2a for
hepatitis C after liver transplantation: two randomized, controlled trials.
Hepatology 2005; 41 (2): 289–98.
14. Recipients: are outcomes worse? [abstract]. Gastroenterology 2004; 126:
A704.
15. Chobrial RM, Farmer DG, Baquerizo A et al. Orthotopic liver transplantation
for hepatitis C: outcome, effect of immunosupression and causes of
retransplantation during an 8-year single-center experience. Ann Surg
1999; 229 (6): 824–31.
16. De Vera ME, Smallwood GA, Rosado K et al. Interferon-alpha and ribavirin
for the treatment of recurrent hepatitis С after liver transplantation.
Transplantation 2001; 71: 678–86.
17. Dumortier J, Scoazec JY, Chevallier P et al. Treatment of recurrent hepatitis
С after liver transplantation: a pilot study of peginterferon a!ra-2b and
ribavirin combination. Hepatol 2004; 40: 669–74.
18. Di Paolo D, Tisone G, Piccolo P et al. Low-dose hepatitis В immunoglobulin
given «on demand» in combination with lamivudine: a highly cost-effective
approach to prevent recurrent hepatitis В virus infection in the long-term
follow-up after liver transplantation. Transplantation 2004; 77: 1203–8.
19. Firpi RJ, Abdelmalek MF, Soldevila-Pico C et al. Combination of interferon
alfa-2b and ribavirin in liver transplant recipients with histological recurrent
hepatitis C. Liver Transpl 2002; 8: 1000–6.
20. Fischer L, Sterneck M, Valentin-Gamazo C et al. Treatment of severe recurrent
hepatitis С after liver transplantation with ribavirin plus interferon
alpha. Transplant Proc 1999; 31: 494–5.
21. Ghobrial RM, Amersi F, Farmer D et al. Rapid and severe early HCV recurrence
following adult living donor liver transplantation. Am J Transpl 2002;
3: A104.
22. Faust D, Rabenau H, Allwinn R et al. Cost-effective and safe
ambulator)'long-term immunoprophylaxis with intramuscular instead of in
travenous hepatitis В immunoglobulin to prevent reinfection after or thotopic
liver transplant. Clin Transplant 2003; 17: 254–8.
23. Guido M, Fagiuoli S, Tessari G et al. Histology predict cirrhotic evolution
of post transplant hepatitis C. Gut 2002; 50 (5): 697–700.
24. Kornberg A, Hommann M, Tannapfel A et al. Long-term combination of
interferon alfa-2b and ribavirin for hepatitis С recurrence in liver transplant
patients. Am J Transplant 2001; 1: 350 5.
25. Curry MP. Hepatitis B and hepatitis C viruses in liver transplantation.
Transplantation 2004; 787: 955–63.
26. Holguin K. Drug Cocktail Prevents Hepatitis B Virus from recurring
after liver transplant. Ann Surg 2002; 5: 794–7.
27. Rodriguez-Luna H, Khatib A, Sharma P et al. Treatment of recurrent
hepatitis С infection after liver transplantation with combination of pegylated
interferon alpha2b and ribavirin: an open-label series. Transplantation
2004; 77: 190–4.
28. Rodriguez-Luna H, Vargas HE, De Petris G et al. Hepatitis С recurrence
in living donor liver transplantation [abstract]. Am J Transpl 2003; 3:
160A.
29. Saab S, Ly D, Han SB et al. Is it cost-effective to treat recurrent hepatitis
С infection in orthotopic liver transplantation patients? Liver Transpl
2002; 8: 449–57.
30. Samuel D, Bizollon T, Feray C et al. Interferon-alpha 2b plus ribavirin
in patients with chronic hepatitis С after liver transplantation: a randomized
study. Gastroenterology 2003; 124: 642–50.
31. Shiffman M, Fisher R, Stravitz R et al. Histological analysis of recurrent
hepatitis С virus infection following live donor and cadaveric transplantation
[abstract]. Am J Transpl 2003; 3.
32. Terrault NA, Khalili M, Straley S et al. Efficacy and tolerability of preemptive
interferon (IFN) versus IFN and ribavirin (RBV) treatment in hepatitis С virus
(HCV) infected liver transplant recipients [abstract]. Hepatology 2003; 38: 158A.
33. Villeneuve JP, Condreay LD, Willems B et al. Lamivudine treatment for
decompensated cirrhosis resulting from chronic hepatitis B. Hepatology
2000; 31: 207–10.
34. Lucey M, Graham D, Martin P et al: Recurrence of hepatitis B and delta
hepatitis after orthotopic liver transplantation. Gut 1992; 33: 1390–5.
35. Wong JB, McQuillan GM, McHutchison JG et al. Estimating future hepatitis
С morbidity, mortality, and costs in the United States. Am J Public Health
2000; 90: 1562–9.
36. Michael P. Curry. Hepatitis B and hepatitis C viruses in liver transplantation.
Transplantation 2004; 78: 955–63.
37. Perretti G, Merli M, Ginanni Corradini S et al. Low-dose intramuscular
hepatitis В immune globulin and lamivudine for long-term prophylaxis of
hepatitis В recurrence after liver transplantation. Transplant Proc 2004; 36:
535–8.
38. Perrillo RP, Wright T, Rakela J et al. A multicenter United States-Canadian
trial to assess lamivudine monotherapy before and after liver transplantation
for chronic hepatitis B. Hepatology 2001; 33: 424–32.
39. Rosen HR, Martin P. Viral hepatitis in the OLT recipient. Semin Liver Dis
2000; 20: 468–80.
40. Schiff E, Ching-Lun L, Neuhaus P et al. Adefovir dipivoxil (ADV) for the
treatment of chronic hepatitis В in patients pre and post liver trans plantation
(OLT) with lamivudine resistance (LAM-R) hepatitis В virus (HBV)
patients. Hepatology 2002; 36: 831–7.